BioCentriq Capacity Update February 2024: Cell & Gene
This presentation form the February 2024 OPCU event offers a comprehensive snapshot of BioCentriq, a leading Contract Development and Manufacturing Organization (CDMO) for cell therapy. Highlighting its global footprint and expertise, BioCentriq showcases its state-of-the-art facilities, established track record in GMP drug product release, and customized solutions supported by a seasoned team with strong commitment to quality. BioCentriq spearheads advancements in CAR-T manufacturing and accelerates clinical development timelines through its innovative LEAP platform, playing a notable role in advancing the accessibility and affordability of cell therapy.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.